By Helena Smolak
Royal Philips is scheduled to report results for the first quarter on Tuesday. Here is what you need to know.
SALES FORECAST: The Dutch health-technology company is expected to post 4.02 billion euros ($4.54 billion) in first-quarter sales, according to a company-compiled consensus, against 4.14 billion euros in the same prior-year period.
ADJUSTED EBITA FORECAST: Philips's adjusted earnings before interest, taxes and amortization is expected at 309 million euros by consensus for the quarter compared to 388 million euros last year.
NET INCOME FORECAST: Analysts estimate that the Amsterdam-listed group will report 19 million euros in first-quarter net income attributable to shareholders--compared with a net loss of 999 million euros in the first quarter of 2024.
As of Friday's market close in Europe, the stock fell 6.9% since the start of 2025.
WHAT TO WATCH
--China: Royal Philips will likely see a sales decline in China in the quarter due to uncertain market conditions on subdued demand for both consumer and health systems in the country, Jefferies and Morgan Stanley analysts said in a note. ING analysts expect a slow start to the year as Philips guided that growth will be back-end loaded.
--Tariffs: Morgan Stanley analysts see higher risks on potential tariff exposure for products in Royal Philips's consumer categories such as electric toothbrushes and razors compared with other of its medtech categories.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 02, 2025 12:53 ET (16:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.